title: Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection.
abstract: BACKGROUND
  Some patients with chronic hepatitis C virus (HCV) infection forego treatment due to concerns about treatment efficacy, treatment duration, and side effects.
  
  
  OBJECTIVE
  The purpose of this study was to quantify patient preferences among possible outcomes associated with new, direct-acting antiviral agents (DAAs) for the treatment of HCV infection and determine which treatment features are most important to patients in making treatment decisions.
  
  
  METHODS
  Adult participants with a self-reported physician diagnosis of HCV infection in five countries completed a web-enabled, choice-format conjoint analysis survey. The survey presented participants with 20 treatment-choice questions. Each treatment-choice question included a pair of hypothetical treatment profiles with varying levels of six attributes: treatment duration; chance of getting rid of the virus completely (i.e. likelihood of a sustained virologic response [SVR]); weeks on an additional, third medicine (i.e. a DAA); risk of a severe rash; risk of severe anemia; and number of times a day the third medicine is taken. Treatment-choice questions were based on a pre-determined experimental design with known statistical properties. Random-parameters logit was used to estimate preference weights for all attribute levels and the mean relative importance of each attribute.
  
  
  RESULTS
  284 participants completed the survey. Likelihood of an SVR was the most important outcome to participants, followed by severe anemia risk, severe rash risk, therapy type (a combination of total weeks of treatment and weeks on the third medicine), and dosing of the third medicine. Controlling for other factors, preferences were similar across all therapy types examined.
  
  
  CONCLUSIONS
  Patients with HCV infection indicate a willingness to accept an increased risk of side effects for sufficient improvement in the likelihood of treatment response.
authors: Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL, USA. tkauf@ufl.edu
authors: Teresa L
authors: TL
authors: Kauf
authors: Ateesha F
authors: AF
authors: Mohamed
authors: A Brett
authors: AB
authors: Hauber
authors: Derek
authors: D
authors: Fetzer
authors: Atiya
authors: A
authors: Ahmad
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002755:Choice Behavior; D003661:Decision Support Techniques; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005060:Europe; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D020407:Internet; D008297:Male; D008875:Middle Aged; D010342:Patient Acceptance of Health Care / Q000523:psychology*; D057240:Patient Preference / Q000523:psychology*; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D000998:Antiviral Agents